Self-quieting, waiting one's turn, and managing anger don't come naturally. They are skills that can be easily taught by parents under your guidance and influence. Includes three Guides for Parents.
Omalizumab increases reaction threshold for multiple common food allergies
Omalizumab was approved by the FDA on February 16, 2024 as the first and only FDA-approved medicine to reduce allergic reactions in patients with 1 or more food allergies.
Food Insecurity and the Dangers of Infant Formula Dilution
Neffy for patients with anaphylactic symptoms after oral food challenge
Thomas Casale, MD, discusses phase 3 data presented at the 2024 AAAAI Meeting in Washington DC, highlighting neffy's efficacy in pediatric patients at risk for anaphylaxis.
Demystifying Infant Formula
Neffy pharmacokinetic profiles compared to epinephrine injections
Sarina Tanimoto, MD, MBA, breaks down a poster session regarding the pharmacokinetic profile of neffy, presented at the 2024 American Academy of Allergy, Asthma, & Immunology Annual Meeting in Washington DC from February 23 to February 26, 2024.
Duchenne muscular dystrophy treatment receives Rare Pediatric Disease designation
The Rare Pediatric Disease Designation joins the Fast Track and Orphan Designations that have already been granted to AOC 1044.
2 Commerce Drive Cranbury, NJ 08512